Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation
Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 17
Healthy Volunteers: f
View:
• Ages 5-17 years old
• Presents to the ED with a respiratory score in the Moderate range (6
• Parent(s)/Caregiver(s) speak English
Locations
United States
Oklahoma
Oklahoma Children's Hospital
RECRUITING
Oklahoma City
Contact Information
Primary
Ryan McKee, MD
ryan-mckee@ouhsc.edu
4056308997
Backup
Jaclyn Urquiola Sorzano, DO
jaclyn-urquiola@ouhsc.edu
7863906297
Time Frame
Start Date: 2023-11-30
Estimated Completion Date: 2025-05-31
Participants
Target number of participants: 100
Treatments
Experimental: Magnesium Sulfate in the first hour
These patients will receive 40-50 mg/kg IV magnesium sulfate within the first hour of treatment alongside all first line asthma exacerbation therapies (ie inhaled beta agonists, IV steroids).
Placebo_comparator: No Magnesium Sulfate
These patients will not receive IV magnesium sulfate within the first hour of treatment but may receive it later if the provider feels it is clinically necessary.
Related Therapeutic Areas
Sponsors
Leads: University of Oklahoma